🇺🇸 FDA
Pipeline program

ION 682884, Placebo injection, 0.8 ml (is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in Water for Injection) for subcutaneous administration

ION-682884-CS2

Phase 3 small_molecule active

Quick answer

ION 682884, Placebo injection, 0.8 ml (is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in Water for Injection) for subcutaneous administration for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) is a Phase 3 program (small_molecule) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
IONIS PHARMACEUTICALS INC
Indication
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials